Solid Biosciences recently reported that it has raised up to $50 million which will enable the biotech to continue to advance its programs for Duchenne muscular dystrophy, including development of a microdystrophin gene. We are forever grateful to our incredible supporters and donors who originally enabled the DRF and other Duchenne charities to assist in providing the seed funding for the gene therapy program.
The DRF and the other charities decided that it was prudent to realise some of their investment in Solid Biosciences in order to continue to support and encourage other avenues of research and programmes as advised by our Scientific Advisory Board, retaining the remainder of their holdings in Solid Biosciences.
We cannot thank our supporters enough for being with us on every step of this journey. Please click here to read more about the ground-breaking projects we have already funded thanks to your support – and there is still more for us to do.
The DRF is committed to continue to raise funds to tackle every aspect of this multi-faceted disease, which affects 1 in 3,500 boys and young men worldwide. We will continue to push to get Duchenne therapies into clinical trials as quickly and safely as possible, in the search for a cure. We also want to ensure that all boys, whether ambulant or non-ambulant, are eligible to participant in clinical trials and get access to vital care and treatments.